Clinical AI Leader Navina Secures $55M Series C Funding Led by Growth Equity at Goldman Sachs Alternatives
Navina, a leader in AI-powered clinical intelligence, has secured a $55 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, bringing total funding to $100 million. The company's AI platform currently serves over 10,000 healthcare professionals across 1,300 clinics, supporting care for more than three million patients.
The platform maintains an 86% weekly active usage rate and has partnerships with industry leaders including agilon health, InnovaCare Health, Millennium Physician Group, and Privia Health. Navina was recently recognized as Best in KLAS 2025 for Clinician Digital Workflow.
The funding will be used to accelerate Navina's U.S. healthcare market expansion, enhance its proprietary AI technology, and improve patient outcomes through proactive clinical intelligence in outpatient interactions.
Navina, un leader nell'intelligenza clinica basata sull'IA, ha ottenuto un finanziamento di 55 milioni di dollari nella Serie C guidato da Growth Equity di Goldman Sachs Alternatives, portando il finanziamento totale a 100 milioni di dollari. La piattaforma AI dell'azienda serve attualmente oltre 10.000 professionisti sanitari in 1.300 cliniche, supportando la cura di oltre tre milioni di pazienti.
La piattaforma mantiene un tasso di utilizzo attivo settimanale dell'86% e ha partnership con leader del settore tra cui agilon health, InnovaCare Health, Millennium Physician Group e Privia Health. Navina è stata recentemente riconosciuta come Best in KLAS 2025 per il Flusso di Lavoro Digitale dei Clinici.
Il finanziamento sarà utilizzato per accelerare l'espansione di Navina nel mercato sanitario degli Stati Uniti, migliorare la sua tecnologia proprietaria di IA e migliorare i risultati per i pazienti attraverso un'intelligenza clinica proattiva nelle interazioni ambulatoriali.
Navina, un líder en inteligencia clínica impulsada por IA, ha asegurado una liderada por Growth Equity de Goldman Sachs Alternatives, llevando la financiación total a 100 millones de dólares. La plataforma de IA de la empresa actualmente sirve a más de 10,000 profesionales de la salud en 1,300 clínicas, apoyando la atención de más de tres millones de pacientes.
La plataforma mantiene una tasa de uso activo semanal del 86% y tiene asociaciones con líderes de la industria, incluyendo agilon health, InnovaCare Health, Millennium Physician Group y Privia Health. Navina fue reconocida recientemente como Best in KLAS 2025 por el Flujo de Trabajo Digital del Clínico.
La financiación se utilizará para acelerar la expansión de Navina en el mercado de salud de EE. UU., mejorar su tecnología de IA propietaria y mejorar los resultados de los pacientes a través de inteligencia clínica proactiva en interacciones ambulatorias.
Navina는 AI 기반 임상 지능의 선두주자로서 5,500만 달러 규모의 시리즈 C 자금 조달을 Goldman Sachs Alternatives의 Growth Equity가 주도하여 총 자금 조달액을 1억 달러로 늘렸습니다. 이 회사의 AI 플랫폼은 현재 10,000명 이상의 의료 전문가에게 서비스를 제공하며, 1,300개의 클리닉에서 300만 명 이상의 환자를 지원하고 있습니다.
이 플랫폼은 주간 활성 사용률이 86%를 유지하고 있으며, agilon health, InnovaCare Health, Millennium Physician Group 및 Privia Health와 같은 업계 리더들과 파트너십을 맺고 있습니다. Navina는 최근 Clinician Digital Workflow 부문에서 KLAS 2025 최고의 기업으로 인정받았습니다.
이번 자금은 Navina의 미국 의료 시장 확장을 가속화하고, 독자적인 AI 기술을 향상시키며, 외래 환자 상호작용에서의 능동적인 임상 지능을 통해 환자 결과를 개선하는 데 사용될 것입니다.
Navina, un leader dans l'intelligence clinique alimentée par l'IA, a sécurisé un financement de 55 millions de dollars lors d'une levée de fonds de Série C dirigée par Growth Equity de Goldman Sachs Alternatives, portant le financement total à 100 millions de dollars. La plateforme IA de l'entreprise sert actuellement plus de 10 000 professionnels de la santé dans 1 300 cliniques, soutenant les soins de plus de trois millions de patients.
La plateforme maintient un taux d'utilisation actif hebdomadaire de 86% et a des partenariats avec des leaders de l'industrie, notamment agilon health, InnovaCare Health, Millennium Physician Group et Privia Health. Navina a récemment été reconnue comme Best in KLAS 2025 pour le flux de travail numérique des cliniciens.
Le financement sera utilisé pour accélérer l'expansion de Navina sur le marché de la santé américain, améliorer sa technologie IA propriétaire et améliorer les résultats pour les patients grâce à une intelligence clinique proactive dans les interactions en ambulatoire.
Navina, ein führendes Unternehmen im Bereich KI-gestützter klinischer Intelligenz, hat eine Finanzierungsrunde der Serie C in Höhe von 55 Millionen Dollar gesichert, die von Growth Equity der Goldman Sachs Alternatives geleitet wurde, wodurch die Gesamtfinanzierung auf 100 Millionen Dollar ansteigt. Die KI-Plattform des Unternehmens bedient derzeit über 10.000 Gesundheitsfachkräfte in 1.300 Kliniken und unterstützt die Versorgung von mehr als drei Millionen Patienten.
Die Plattform hat eine wöchentliche aktive Nutzungsrate von 86% und hat Partnerschaften mit Branchenführern wie agilon health, InnovaCare Health, Millennium Physician Group und Privia Health. Navina wurde kürzlich als Best in KLAS 2025 für den digitalen Workflow von Kliniken ausgezeichnet.
Die Finanzierung wird verwendet, um die Expansion von Navina auf dem US-Gesundheitsmarkt zu beschleunigen, die proprietäre KI-Technologie zu verbessern und die Patientenergebnisse durch proaktive klinische Intelligenz in der ambulanten Versorgung zu optimieren.
- Secured $55M Series C funding, bringing total funding to $100M
- Strong market presence with 10,000+ healthcare professionals across 1,300 clinics
- High platform engagement with 86% weekly active usage rate
- Recognized as Best in KLAS 2025 for Clinician Digital Workflow
- Established partnerships with major healthcare organizations
- None.
Insights
Goldman Sachs Alternatives' Growth Equity division is leading a
This investment aligns with Goldman's strategic expansion into growth-stage technology companies, particularly those positioned at the intersection of AI and healthcare transformation. Navina has established meaningful market traction with 10,000+ healthcare professionals across 1,300 clinics and relationships with notable healthcare organizations.
For Goldman Sachs, this represents business-as-usual activity for its Alternatives division, which encompasses private equity, growth equity, and venture investments. The deal size isn't material enough to impact GS's financial performance or stock valuation, but it does reflect the firm's ongoing diversification beyond traditional investment banking.
The healthcare AI sector offers substantial growth potential as the U.S. healthcare system transitions toward value-based care models that prioritize outcomes over volume. Goldman's participation signals institutional confidence in both Navina's technology and the broader market opportunity, though returns will materialize only over a multi-year horizon typical of growth equity investments.
Investment will fuel the advancement of its AI-powered clinical intelligence platform, transforming patient care and value-based care outcomes
This significant investment will accelerate Navina's expansion across the
"This investment is a powerful validation of Navina's vision to improve patient outcomes and healthcare economics by breaking down data barriers with AI," said Ronen Lavi, co-founder and CEO of Navina. "We're thrilled to partner with a best-in-class firm like Goldman Sachs, whose market leadership will be instrumental as we enter this pivotal growth phase and expand our market reach. With this additional capital, we will continue to accelerate AI innovation and revolutionize healthcare by making every patient interaction more empathic, personalized, and proactive."
Navina's AI copilot has rapidly established itself as the trusted solution for value-based care organizations, beginning with primary care and expanding to broader healthcare segments. The platform serves over 10,000 healthcare professionals across 1,300 clinics and supports the care of more than three million patients. The company has already secured partnerships with industry leaders including agilon health, InnovaCare Health, Millennium Physician Group, and Privia Health, and was recently recognized as Best in KLAS 2025 for Clinician Digital Workflow, further validating its exceptional customer satisfaction and trust.
"AI is rapidly transforming modern healthcare, and Navina stands at the forefront of that transformation – delivering real, measurable value to thousands of clinicians," said Irit Kahan, Managing Director in Growth Equity at Goldman Sachs Alternatives. "Their deep integration into clinical workflows, unparalleled provider trust, and demonstrated ROI make them uniquely positioned to drive meaningful impact across the healthcare ecosystem. We believe Navina's AI-powered platform is a game-changer, and we are excited to support their next stage of growth."
As healthcare continues to transition toward value-based care, the need for accurate and timely clinical intelligence has become more critical than ever. Yet fragmented data, inefficient manual workflows, and growing administrative burdens make it difficult for clinicians to deliver proactive, preventive patient care, resulting in poor clinical outcomes and high cost of care.
Navina equips clinicians and care teams with real-time, data-driven insights that improve the quality of care and financial outcomes. Navina's AI copilot surfaces clinical insights that support effective decision-making throughout the care continuum–from the back office to the point of care–while significantly reducing the administrative burden. Navina natively integrates into the clinician workflow, and maintains an impressive
With this funding, Navina will accelerate the development of its proprietary AI to ultimately become the definitive source of unified patient data that improves efficiency and care quality across the ecosystem from payers to providers. The company will expand its platform capabilities to further automate and optimize workflows from proactive population health management to effective point-of-care intervention.
About Navina
Navina's AI copilot brings clinical intelligence to clinicians and care teams, transforming care and value-based outcomes. Navina's powerful AI turns fragmented patient data into a concise patient profile with actionable insights at every clinical touchpoint. Designed for and loved by physicians, Navina reduces missed diagnoses, improves quality metrics and risk adjustment accuracy, and alleviates the administrative burden—allowing providers to focus on what matters most: their patients. Privia Health, agilon health, and Millennium Physician Group are among some of the leading value-based care organizations leveraging Navina's AI copilot to enhance clinician workflows and improve quality performance. The company was selected Best in KLAS 2025 for Clinician Digital Workflow, and won recognition in the 2024 MedTech Breakthrough Awards, KLAS Emerging Solutions Top 20 report, and the CB Insights Digital Health 50 list.
About Growth Equity at Goldman Sachs Alternatives
Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over
The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets.
The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world's leading institutions, financial advisors and individuals. Goldman Sachs has more than
Since 2003, Growth Equity at Goldman Sachs Alternatives has invested over
MEDIA CONTACT:
For Goldman Sachs Asset Management
Joseph Stein, +44 207 774 2523
FOR NAVINA:
Brook Terran
Evergreen & Oak for Navina
336-269-7001
brook@evergreenandoak.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-ai-leader-navina-secures-55m-series-c-funding-led-by-growth-equity-at-goldman-sachs-alternatives-302410452.html
SOURCE Navina
FAQ
How much funding did Navina raise in its Series C round led by Goldman Sachs (GS)?
What is Navina's current market reach and user base in 2025?
What recognition did Navina receive in 2025?
What is the user engagement rate for Navina's AI platform?
Which major healthcare organizations have partnered with Navina?
